Cholesterol drug showdown: which one do patients actually take?

NCT ID NCT07468500

Not yet recruiting Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inclisiran and evolocumab
What this could lead to: If successful, this study could show which cholesterol-lowering drug patients are more likely to take regularly, helping doctors choose better treatments.
What could go wrong: This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to people outside Japan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias familial hypercholesterolemia Hypercholesterolemia hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA HYPERCHOLESTEROLEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.